UBS lowered the firm’s price target on CVS Health (CVS) to $67 from $71 and keeps a Neutral rating on the shares. UBS says the firm is tempering its expectations for Q2, and feels that the reiteration of guidance is “good enough,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- ACA marketplace plans seek double digit rate increases for 2026, WSJ says
- U.S. Health insurers prescription drug denials on the rise, NYT says
- CVS Snatches CalPERS Pharmacy Contract from UnitedHealth
- Trump Trade: U.S. slaps 30% tariff rate on EU, Mexico
- Fight brewing over Medicare drug negotiation program, Bloomberg Law reports